KalVista Pharmaceuticals, Inc. (KALV)
15.90
-1.00
(-5.92%)
USD |
NASDAQ |
Dec 16, 16:00
15.89
-0.01
(-0.06%)
After-Hours: 20:00
KalVista Pharmaceuticals Research and Development Expense (Annual): 76.72M for April 30, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 173.39M |
| Iovance Biotherapeutics, Inc. | 282.34M |
| Travere Therapeutics, Inc. | 217.50M |
| Xenetic Biosciences, Inc. | 2.584M |
| BeyondSpring, Inc. | 2.644M |